Newron Pharmaceuticals (Italy)

Recent papers from Newron Pharmaceuticals (Italy)

1. Toxicity Aspects in Safe and Sustainable by Design Framework: An Assessment of ToolsACS Sustainable Chemistry & Engineering · 2026
2. Assessing the Value of Sustainability in the Citrus Supply ChainSustainability · 2026
3. The Use of Physical Energy-Based Therapies in the Management of OsteoarthritisMedicina · 2026
4. Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trialsTherapeutic Advances in Psychopharmacology · 2026
5. Circulating microRNAs as biomarkers in pediatric epilepsy: A longitudinal cohort study.2026
6. The effect of highly bioavailable forms of curcumin on lipoprotein(a) plasma levels: A systematic review and meta-analysis of randomized clinical studiesProstaglandins & Other Lipid Mediators · 2025
7. Proceedings of the 12th annual deep brain stimulation think tank: cutting edge technology meets novel applicationsFrontiers in Human Neuroscience · 2025
8. Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trialNeuropharmacology · 2024
9. Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical TrialThe International Journal of Neuropsychopharmacology · 2024
10. Adaptive vs. Conventional Deep Brain Stimulation: One-Year Subthalamic Recordings and Clinical Monitoring in a Patient with Parkinson’s DiseaseBioengineering · 2024
11. Proceedings of the 11th Annual Deep Brain Stimulation Think Tank: pushing the forefront of neuromodulation with functional network mapping, biomarkers for adaptive DBS, bioethical dilemmas, AI-guided neuromodulation, and translational advancementsFrontiers in Human Neuroscience · 2024
12. One-year subthalamic recordings in a patient with Parkinson’s disease under adaptive deep brain stimulation2023
13. Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant SchizophreniaThe International Journal of Neuropsychopharmacology · 2023
14. Long Covid: where we stand and challenges aheadCell Death and Differentiation · 2022
15. A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracisFrontiers in Microbiology · 2022
16. Double-blind cross-over pilot trial protocol to evaluate the safety and preliminary efficacy of long-term adaptive deep brain stimulation in patients with Parkinson’s diseaseBMJ Open · 2022
17. A New Implantable Closed-Loop Clinical Neural Interface: First Application in Parkinson’s DiseaseFrontiers in Neuroscience · 2021
18. Eight-hours conventional versus adaptive deep brain stimulation of the subthalamic nucleus in Parkinson’s diseaseSHILAP Revista de lepidopterología · 2021
19. Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paperBritish Journal of Clinical Pharmacology · 2021
20. The Relationship Between Electrical Energy Delivered by Deep Brain Stimulation and Levodopa-Induced Dyskinesias in Parkinson's Disease: A Retrospective Preliminary AnalysisFrontiers in Neurology · 2021